KALEN SUNDEEN: Open Payments
NPI 1366000671 · CLOVERDALE, IN. Company-reported industry payments from CMS Open Payments. A payment does not imply wrongdoing.
See the full provider profile for registry, prescribing and billing details.
Industry payments (Sunshine Act)
Source: CMS Open Payments general payments. Payments from drug and device companies are reported by the companies; they do not imply wrongdoing and are separate from Medicare billing.
$832 in 43 payments from 17 companies in 2025. Trend: 2023 $1,632 · 2024 $1,710 · 2025 $832
Food & beverage: $832
| Company | Payments | Amount |
|---|---|---|
| Novo Nordisk Inc | 7 | $147 |
| ABBVIE INC. | 8 | $138 |
| Axsome Therapeutics, Inc. | 3 | $78 |
| Otsuka America Pharmaceutical, Inc. | 3 | $63 |
| AstraZeneca Pharmaceuticals LP | 4 | $61 |
| Lilly USA, LLC | 3 | $60 |
| Abbott Laboratories | 2 | $46 |
| Bayer Healthcare Pharmaceuticals Inc. | 2 | $36 |
| Corium, LLC | 2 | $32 |
| GlaxoSmithKline, LLC. | 2 | $30 |
Products named: Auvelity, REXULTI, QULIPTA, VRAYLAR, FREESTYLE LIBRE 3, MOUNJARO, Kerendia, BREZTRI.
Industry payments across IN — which companies pay providers there.
